| Popis: |
We have recently shown that In normal subjects aspirin (1,300 mg) and Indobufen (400 mg), a new cyclo-oxygenase Inhibitor structurally unrelated to salycilate, lower the fibrinolytic activity, without modifying t-PA antigen levels, after venous occlusion (VO). The aim of this study was to investigate whether aspirin reduces fibrinolytic response to VO also In patients with TIA. These patients were selected In view of controlled clinical trials showing reduction of TIA recurrency and stroke by treatment with high dose aspirin. Six males (56-65 yrs old), with previous TIA (< 1 year) were selected; the presence of diffuse atherothrombotlc lesions was demonstrated by doppler sonography and angiography. All patients were given, ten days apart, aspirin (600 mg daily x 2) or Indobufen (200 mg daily x 2) following a randomized cross-over single blind scheme. In all patients 10 minutes VO applied before any drug administration, Induced activation of the fibrinolytic system as assessed by euglobulin lysis area on fibrin plates (from 226±47 to 643±57 mm2), t-PA antigen (from 13.8± 1.0 to 40.9±3.1 ng/ml) and PA-1 activity (from 39.5+5.0 to 14.8±1.6 AU/ml). Neither aspirin nor Indobufen Ingestion resulted In any Inhibitory effect on fibrinolytic response to VO while both drugs suppressed serum thromboxane 02 generation by more than 98%. In conclusion high dose aspirin and Indobufen do not Impair the fibrinolytic potential In TIA patients with atherothrombotlc lesions. The reasons for the different behaviour of patients In respect to young healthy volunteers remain to be established. |
